Aeterna Zentaris Inc. (AEZS)

Oncology Corporate Profile

Stock Performance

2.7000
-0.1000

HQ Location

20 Independence Blvd
Warren, NJ 07059

Company Description

Æterna Zentaris Inc. is a late-stage oncology drug development company currently investigating potential treatments for various cancers including colorectal, multiple myeloma, endometrial, ovarian, prostate and bladder cancer.The Company’s innovative approach of "personalized medicine" means tailoring treatments to a patient’s specific condition and to unmet medical needs. Aeterna Zentaris’ deep pipeline is drawn from its proprietary discovery unit providing the Company with constant and long-term access to state-of-the-art therapeutic options.

Website: http://www.aezsinc.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
zoptarelin doxorubicin / AEZS-108cytotoxic peptide conjugate2nd line metastatic Endometrial cancerIII
zoptarelin doxorubicin / AEZS-108cytotoxic peptide conjugateBladder cancerII
zoptarelin doxorubicin / AEZS-108cytotoxic peptide conjugateBreast cancerII
AEZS-130growth hormone secretagogues (GHS) Cancer cachexiaII
zoptarelin doxorubicin / AEZS-108cytotoxic peptide conjugateOvarian cancerII
zoptarelin doxorubicin / AEZS-108cytotoxic peptide conjugateOvarian cancer II
zoptarelin doxorubicin / AEZS-108cytotoxic peptide conjugateProstate cancerII
perifosine / KRX-0401AKT inhibitorNeuroblastomaI
perifosine / KRX-0401AKT inhibitorVarious cancer typesI
AEZS-112topoisomerase II inhibitorVarious cancer typesI
perifosine (+ trastuzumab) / KRX-0401AKT inhibitorBreast cancerII
perifosine / KRX-0401AKT inhibitorNon Small cell Lung Cancer (NSCLC)II
perifosine / KRX-0401AKT inhibitorRenal cell carcinoma (RCC)II
perifosine / KRX-0401AKT inhibitorSarcomaII
perifosine (+ imatinib) / KRX-0401AKT inhibitorSarcomaII
ozarelix / SPI-153LHRH antagonistVarious cancer typesII Spectrum Pharmaceuticals
AEZS-120 immunotherapyMelanomaPreclinical
AEZS-120 immunotherapyProstate cancerPreclinical
AEZS-125 (LHRH-Disorazol Z) LHRH antagonistVarious cancer typesPreclinical
AEZS-137 (disorazol Z)microtubule inhibitorVarious cancer typesPreclinical
AEZS-136PI3K/Erk dual inhibitorVarious cancer typesPreclinical

View additional information on product candidates here »

Source


http://www.aezsinc.com

Recent News Headlines

Aeterna Zentaris Reports Fourth Quarter and Full-Year 2016 Financial and Operating Results

3/15/2017 08:04 pm

[Business Wire] - Aeterna Zentaris Inc. , a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology and endocrinology, today reported financial and operating results for the fourth quarter and year ended December 31, 2016.

Aeterna Zentaris Announces EMA Pediatric Committee Agreement on the Pediatric Investigation Plan for Macrilen™

3/7/2017 01:03 pm

[Business Wire] - Aeterna Zentaris Inc. announced today that the Pediatric Committee of the European Medicines Agency agreed to the Company’s Pediatric Investigation Plan for Macrilen™ and agreed that the Company may defer conducting the PIP until after it files a Marketing Authorization Application seeking marketing authorization for the use of Macrilen™ for the evaluation of adult growth hormone deficiency.

Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2016 Financial and Operating Results on March 15, 2017

3/6/2017 01:03 pm

[Business Wire] - Aeterna Zentaris Inc. will announce its fourth quarter and full-year 2016 financial and operating results after market close on Wednesday, March 15, 2017.

Aeterna Zentaris Announces Presentation Regarding Macrilen™ at 99th Annual Meeting of the Endocrine Society

3/2/2017 10:00 pm

[Business Wire] - Aeterna Zentaris Inc. today announced that Jose M. Garcia, M.D., Ph.D., an Associate Professor of Medicine at the Puget Sound Veterans Administration Hospital and the University of Washington, will present an abstract entitled “Validation of Macimorelin as a Diagnostic Test for Adult Growth Hormone Deficiency : A Phase 3 Study in Comparison with the Insulin Tolerance Test ” from 1:00 pm through 3:00 ...

Aeterna Zentaris Announces Zoptrex™ Presentation in Prostate Cancer at 2017 Genitourinary Cancers Symposium

2/14/2017 10:03 pm

[Business Wire] - Aeterna Zentaris Inc. today announced that a poster entitled, “A phase II trial of zoptarelin doxorubicin in castration-and taxane-resistant prostate cancer”, will be presented during the 2017 Genitourinary Cancers Symposium’s “Translating Research to Value-based and Patient-centric Care” by lead investigator, and co-author of the presentation, Jacek Pinski, MD, PhD, USC Norris Comprehensive Cancer ...

Aeterna Zentaris Announces Plans to Pursue FDA Registration of Macrilen™

2/13/2017 12:03 pm

[Business Wire] - Aeterna Zentaris Inc. today announced that, following a comprehensive review of data obtained from the confirmatory Phase 3 clinical trial of Macrilen™ for the evaluation of growth hormone deficiency in adults , using the insulin tolerance test as a comparator, it concluded that Macrilen™ demonstrated performance supportive of achieving registration with the U.S.

Aeterna Zentaris to Present at the 2nd Annual Disruptive Growth & Healthcare Conference

2/9/2017 01:03 pm

[Business Wire] - Aeterna Zentaris Inc. , announced today that it will be presenting at the 2nd Annual Disruptive Growth & Healthcare Conference on Thursday, February 16 at 9:30 AM EST.

Aeterna Zentaris to Present at the 2017 BIO CEO and Investor Conference

2/7/2017 09:01 pm

[Business Wire] - Aeterna Zentaris Inc. today announced that it will be presenting at the 2017 BIO CEO & Investor Conference on Monday, February 13 at 8:00 AM EST in New York City.

Drug Approvals Expected to Rise as Trump Pledges to Speed Up Approval Process: Latest Reports on AEterna Zentaris and Momenta Pharmaceuticals

2/1/2017 02:04 pm

[Accesswire] - NEW YORK, NY / ACCESSWIRE / February 1, 2017 / The Biotech Industry has outperformed the broader markets in 2017, despite all the criticism drug makers have been facing. The iShares NASDAQ Biotechnology ...

Aeterna Zentaris Announces Completion of Zoptrex™ Pivotal Phase 3 Clinical Trial in Advanced Endometrial Cancer; Expects to Report Top-Line Results in April 2017

1/30/2017 10:03 pm

[Business Wire] - Aeterna Zentaris Inc. today announced the occurrence of the 384th death in the pivotal Phase 3 ZoptEC study with Zoptrex™ in women with advanced, recurrent or metastatic endometrial cancer, representing the clinical endpoint of the study.

Biotech Industry Outperforming Markets in 2017: Latest Reports on Pulmatrix and Aeterna Zentaris

1/18/2017 02:03 pm

[Accesswire] - NEW YORK, NY / ACCESSWIRE / January 18, 2017 / Biotech and Pharmaceutical companies took a hit last week after President Trump criticized the drug industry at a press conference. Today's reports on Pulmatrix ...

01.04.2017 Aeterna Zentaris Announces Top-Line Results of Confirmatory Phase 3 Trial of Macrilen™

1/5/2017 12:00 am

[at noodls] - CHARLESTON, S.C.--(BUSINESS WIRE)--Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the 'Company') today announced that the confirmatory Phase 3 clinical trial of Macrilen™ (macimorelin)failed to achieve ...

Aeterna Zentaris Announces Top-Line Results of Confirmatory Phase 3 Trial of Macrilen™

1/4/2017 10:01 pm

[Business Wire] - Aeterna Zentaris Inc. today announced that the confirmatory Phase 3 clinical trial of Macrilen™ failed to achieve its objective of validating a single oral dose of macimorelin for the evaluation of growth hormone deficiency in adults , using the insulin tolerance test as a comparator.